SoftBank's investment into Biofourmis strikes a note of optimism for the troubled digital therapeutics space. : Biofourmis is part of a small but growing group of venture-backed start-ups looking to augment traditional medicines with digital technology, including wearables and software. The hope for these kinds of digital-drug combinations is to add personalization to medicine to help ensure the right patient gets access to the right drug at the right time. Not all medicines work well for every patient. By tracking how patients are faring outside of the hospital, doctors might suggest a change in dosage or a different combination of drugs.